Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marjorie C Green

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2010
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersGiampaolo Bianchini, Yuan Qi, Ricardo H Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancerCatherine M Kelly, Marjorie C Green, Kristine Broglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenAman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green, Aman U Buzdar, Terry Smith, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar, Nuhad K Ibrahim, Deborah Francis, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2010
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancersGiampaolo Bianchini, Yuan Qi, Ricardo H Alvarez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancerCatherine M Kelly, Marjorie C Green, Kristine Broglio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 4, 2007
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenAman U Buzdar, Vicente Valero, Nuhad K Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeksMarjorie C Green, Aman U Buzdar, Terry Smith, et al.
Cancer|June 5, 2003
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinomaW Fraser Symmans, Mark Ayers, Edwin A Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerAman U Buzdar, Nuhad K Ibrahim, Deborah Francis, et al.
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Lancet (London, England)|May 14, 2019
Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trialBrian I Rini, Thomas Powles, Michael B Atkins, et al.
Pageof 2